Parafilm to Prevent CLABSI in Pediatric Patients Undergoing HCT
| Status: | Completed |
|---|---|
| Conditions: | Infectious Disease |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | Any - 21 |
| Updated: | 11/23/2018 |
| Start Date: | March 2015 |
| End Date: | March 29, 2018 |
Parafilm Application to Prevent Central Line Associated Bloodstream Infections in Pediatric Patients Undergoing Hematopoietic Cell Transplantation
The purpose of this study is to see if applying parafilm as an external barrier on the
central line in children having a bone marrow transplant helps to prevent central line
associated bloodstream infection(s) and also to assess the ease of use of parafilm.
central line in children having a bone marrow transplant helps to prevent central line
associated bloodstream infection(s) and also to assess the ease of use of parafilm.
Central line associated bloodstream infections (CLABSI) result in significant morbidity and
mortality, particularly in patients undergoing hematopoietic cell transplantation (HCT). HCT
patients are at high risk for CLABSI due to multiple factors, including prolonged immune
suppression and the need for long-term central venous access. The investigators want to
assess the feasibility of the use of a parafilm central line barrier (parafilm) as standard
of care in pediatric HCT patients. The investigators will also assess the effectiveness of
the parafilm to reduce the incidence of CLABSI in these patients.
mortality, particularly in patients undergoing hematopoietic cell transplantation (HCT). HCT
patients are at high risk for CLABSI due to multiple factors, including prolonged immune
suppression and the need for long-term central venous access. The investigators want to
assess the feasibility of the use of a parafilm central line barrier (parafilm) as standard
of care in pediatric HCT patients. The investigators will also assess the effectiveness of
the parafilm to reduce the incidence of CLABSI in these patients.
Inclusion Criteria:
- Must be between the age of 0 and 21 years at the time of enrollment
- Must be undergoing allogeneic or autologous HCT for a malignant or non-malignant
disorder
- Must have or be scheduled to have a tunneled CVC
Exclusion Criteria:
- Patients undergoing other interventions to prevent CLABSI (e.g. Children's Oncology
Group (COG) study ACCL1034 with Chlorhexidine Gluconate (CHG); antimicrobial lock
therapy, etc.)
- Patients who only have a port
We found this trial at
1
site
1405 Clifton Road NE
Atlanta, Georgia 30322
Atlanta, Georgia 30322
404-785-6000
Principal Investigator: Elizabeth Stenger, MD
Phone: 404-785-1272
Children's Healthcare of Atlanta Whether treating a toddler in an emergency or supporting a teen...
Click here to add this to my saved trials
